Clene Announces $4 Million Registered Direct Offering
Clene raises $4 million from insider-led existing shareholders, aiming to extend its cash runway into mid-first quarter 2027.
Rhea-AI Summary
Clene (CLNN) has priced a registered direct offering of 1,219,513 shares of common stock at $3.28 per share to existing shareholders, for total gross proceeds of $4 million, with closing expected on September 17, 2026.
The investment is led by Clene’s chairman David Matlin, founding investor Kensington Capital Holdings, the chief executive officer and other existing shareholders, and is being conducted without a placement agent, underwriter, broker or dealer. Clene expects the proceeds, together with existing cash, to fund operations through mid-first quarter 2027 and plans to use the funds primarily for general corporate purposes and to support regulatory dialogue, filings, expanded access protocols, potential commercialization and manufacturing expansion for CNM-Au8.
Positive
- Insider-led financing provides $4 million of gross proceeds
- Offering is expected to fund operations through mid-Q1 2027
- No placement agent or underwriter used, potentially reducing transaction costs
Negative
- Issuance of 1,219,513 new shares dilutes existing shareholders
- Proceeds extend runway only into mid-first quarter 2027, implying further funding may be needed thereafter
News Explained
If the September 17 closing occurs, 1,219,513 new shares would dilute existing ownership; the $4 million is priced, not yet closed.
Clene has priced the issuance of
A registered direct is a negotiated sale of registered securities to selected investors. The company is using its S-3 shelf for registration capacity, while the prospectus supplement will state the specific offering terms; neither changes the fact that closing remains expected rather than completed.
The specified checkpoints are the expected
Details
Market reaction after $4 million registered direct offering: CLNN +12.49%
Following this news, CLNN has gained 12.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.3% during the session. Our momentum scanner has triggered 20 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $3.69. Trading volume is exceptionally heavy at 14.6x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Gross proceeds
- $4 million
- Registered direct offering
- Shares offered
- 1,219,513 shares
- Registered direct offering
- Purchase price
- $3.28 per share
- Priced at market under Nasdaq rules
- Expected closing
- September 17, 2026
- Offering closing date
- Operating runway
- mid-first quarter 2027
- Expected funding period
Previous Offering Reports
-
Clene priced a $7 million underwritten registered direct offering
-
Clene announced a registered direct offering exceeding $28 million
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
registered direct offering financial
shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders
$4 million registered direct offering priced at market under Nasdaq rules- Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027
SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of
The offering was led by Clene’s Chairman of the Board of Directors, David Matlin, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders.
The offering is expected to provide Clene with sufficient cash to fund its operations through mid-first quarter 2027.
The offering is being made without a placement agent, underwriter, broker or dealer. Clene intends to use the proceeds, together with its existing cash, for expenses primarily related to general corporate purposes, including to fund the effort supporting the continued regulatory dialogue and preparation of regulatory filings for CNM-Au8, including expanded access protocols, potential future commercialization efforts and manufacturing expansion.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-286058), previously filed with the Securities and Exchange Commission (SEC) under the Securities Act of 1933, as amended. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock. Clene will not sell any of the shares of common stock in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Clene
Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding the timing of the closing of the offering. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; the post hoc and exploratory nature of the biomarker analyses described in this press release, which were not prespecified, were not adjusted for multiplicity, and are based on small patient numbers, and which may not be predictive of results in future trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is participating in Clene’s $4 million registered direct offering?
The offering is led by Clene’s chairman of the board of directors David Matlin, alongside founding investor Kensington Capital Holdings, Clene’s chief executive officer and other existing shareholders.
What are the key terms of Clene’s registered direct offering?
Clene is offering 1,219,513 shares of common stock at a purchase price of $3.28 per share to existing shareholders, including insiders, for total gross proceeds of $4 million. The closing is expected on September 17, 2026.
How does Clene plan to use the proceeds from this offering?
Clene intends to use the proceeds, together with its existing cash, for general corporate purposes and to fund efforts supporting continued regulatory dialogue and preparation of regulatory filings for CNM-Au8, including expanded access protocols, potential future commercialization efforts and manufacturing expansion.
Under what registration statement is the offering being made?
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286058), previously filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended.
Where can investors find the final prospectus supplement for this offering?
A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.